LC3-II Puncta (ICC/IHC/IF): This method combines the use of antibodies to LC3 and fluorescence microscopy to quantify fluorescent puncta, which correlate with the number of autophagosomes. This assay reports the number of puncta per cell or number of cells with puncta. Generally, basal autophagic activity is present and therefore most cells will have puncta. Immunocytochemistry/Immunofluorescence: Confocal analysis of HeLa cells using LC3B antibody ([NB600-1384], 1:5,000). An Alexa Fluor 488-conjugated Goat anti-rabbit IgG was used as secondary antibody (Green). Actin filaments were labeled with Alexa Fluor 568 Phalloidin (Red). DAPI was used to stain the cell nuclei (Blue). Protocols Inhibition of Autophagy and LC3B Antibody (NB100-2220) Immunocytochemistry (ICC) Immunohistochemistry-Paraffin Protocol for LC3B/MAP1LC3B Antibody (NB100-2220) |
LC3-Conversion (WB): This method measures the conversion of LC3, from unlipidated LC3-I to the lipidated form LC3-II. An increased conversion ratio correlates with increased autophagosome number. Quantification should be based on the comparison of LC3-II levels to the levels of a housekeeping protein (e.g., actin). In some systems, the levels of housekeeping proteins are affected by autophagy and LC3-I may be used for comparison.
|
||||||||||||||||||||||||
|
LC3 Turnover Assay (WB, ICC/IF): This assay monitors the accumulation of autophagosomes to determine autophagic flux. Reagents that block autophagic flux and prevent LC3-II degradation including lysosomotropic agents and protease inhibitors are commonly used. The difference in the amount of LC3-II in the presence and absence of these agents provides a measure of autophagic flux. This assay allows researchers to distinguish between true autophagy induction and blockade of autophagic flux.
HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) were untreated (-) or treated (+) with 50 μM Chloroquine for 18 hours. Whole cell protein lysates were prepared in 1x Laemmli sample buffer and approximately 10 μg of each lysate was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 μm PVDF membrane and blocked in 5% non-fat milk in TBST. PVDF membranes were probed with (A) rabbit anti- LC3B polyclonal [NB100-2220] and (B) rabbit anti-LC3B monoclonal [NBP2-46892] followed by HRP conjugated anti-rabbit IgG secondary antibody. A specific band was detected for LC3B at approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions. |
||||||||||||||||
Reagents for Autophagy Turnover Assay
Available at Tocris: www.tocris.com Protocols Inhibition of Autophagy and LC3B Antibody (NB100-2220) Western Blot Western Blot Protocol for p62/SQSMT1 Antibody (NBP1-48320) Western Blot Protocol for Atg5 Antibody (NB110-53818) Western Blot Protocol for Atg16L1 Antibody (NB110-60928) |
p62/SQSTM1 Degradation Assay (WB, FC, ELISA, ICC/IF): Removal of cytosolic p62/SQSTM1 occurs primarily by autophagy. Therefore, the level of p62/SQSTM1 is inversely correlated to autophagic activity. Similar to LC3-II, blocking degradation of cytosolic components with Chloroquine, inhibits autophagic flux and leads to the accumulation of p62/SQSTM1. The levels of p62/SQSTM1 may be quantitated by flow cytometry, immunoblot and ELISA and serves as a biomarker for the analysis of autophagic flux.
HeLa cells mock (left) and treated with 50 μM Chloroquine for 24 hours (right) were fixed in 4% paraformaldehyde at room temperature for 15 minutes. (Green): SQSTM1 protein stained by SQSTM1 antibody (1478) [NBP2-43663] diluted at 1:1000. (Red): Actin stained with Phalloidin diluted at 1:200. (Blue): Hoechst 33342 staining. |
||||||||||||
Additional Targets to Monitor Autophagy
*ULK1 serves as a switch for autophagy regulation, mTOR and AMPK directly phosphorylate ULK1 inhibiting or activating its function, respectively. |